PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2020 | 10 | 2 | 62-68
Article title

Complete response to pixantrone as a salvage therapy in a relapsed/refractory diffuse large B-cell lymphoma

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). It is one of the most common form of the disease. A combination of chemotherapy with anthracycline and a monoclonal antibody targeting CD20 is used as a I line therapy. About two out of three people with DLBCL achieve and maintain complete remission after this treatment. In case of relapse or refractory disease a salvage high‑dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is the standard of care. Patientrs who relapse after HD-ASCT have a very poor prognosis. Pixantrone is a new anthracycline derivative registered to treat relapsed/refractory DLBCL in adult patients. It is a cytostatic agent with a reduced cardiotoxicity comparing to classic anthracyclines. Herein, we report two cases of relapsed/refractory DLBCL treated with pixantrone as a salvage therapy. The first case concernes a 58-year-old female patient with a diagnose of DLBCL, who relapsed after four prior lines of therapy (R-CHOP, ICE, HD-Mtx, CSN radiation) and achieved complete remission after pixantrone therapy, but died of acute myeloid leukemia 3 months after the end of treatment. Second case is a story of a 75-year-old female patient treated with two prior lines of treatment (R-CHOP, R-IVE), who achieved complete remission after a III line of therapy with pixantrone. Pixantrone monotherapy proves to be effective in relapsed/refractory DLBCL. This treatment is well tolerated in a group of elderly patients and can be also used in a group of patients with a limited cardiac function.
Discipline
Publisher

Journal
Year
Volume
10
Issue
2
Pages
62-68
Physical description
Contributors
  • Clinical Department of Hematology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland
References
  • 1. Warzocha K, Puła B. Rozpoznawanie i leczenie chorych na chłoniaka rozlanego z dużych komórek B. Hematologia. 2017; 8(2): 113-31.
  • 2. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene. 2004; 23(38): 6524‐34. http://doi.org/10.1038/sj.onc.1207843.
  • 3. Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019; 380(1): 45‐56. http://doi.org/10.1056/NEJMoa1804980.
  • 4. McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38(4): 1484‐93. http://doi.org/10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i.
  • 5. Neumann D, Korzeniowska K, Jankowski J et al. Kardiotoksyczność leczenia przeciwnowotworowego. Choroby Serca i Naczyń. 2016; 13(6): 434-44.
  • 6. Dudziak J, Słomczyński M, Torliński L. Powikłania kardiologiczne po chemioterapii – patomechanizm, diagnostyka, leczenie i zapobieganie. Choroby Serca i Naczyń. 2009; 6(2): 73-9.
  • 7. Piętka I, Lelonek M. Kardiomiopatia poantracyklinowa – diagnostyka, leczenie i zapobieganie. Folia Cardiol Excerpta. 2010; 5(3): 130-4.
  • 8. Péan E, Flores B, Hudson I et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2013; 18(5): 625-33.
  • 9. Pettengell R, Coiffier B, Egorov A et al. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non- Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial. Clin Drug Investig. 2018; 38(6): 527‐33. http:// doi.org/10.1007/s40261-018-0635-3.
  • 10. Pettengell R, Coiffier B, Narayanan G et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial [published correction appears in Lancet Oncol. 2012; 13(7): e285]. Lancet Oncol. 2012; 13(7): 696‐706. http://doi.org/10.1016/S1470-2045(12)70212-7.
  • 11. Piksantron w leczeniu chłoniaków złośliwych. https://www.gov.pl/web/zdrowie/choroby-onkologiczne.
  • 12. CTI Life Sciences Limited. Pixuvri: summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__ Product_Information/human/002055/ WC500127968.pdf (Access: 10.07.2017).
  • 13. Schmitz R, Wright GW, Huang DW et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15): 1396‐407. doi:10.1056/NEJMoa1801445.
  • 14. Kaczmarczyk A, Giannopoulos K. Zmiany genetyczne w chłoniaku rozlanym z dużych komórek B. Acta Haematologica Polonica. 2019; 50(4): 204-14.
  • 15. Pettengell R, Sebban C, Zinzani PL et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non- Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016; 174(5): 692‐9. http://doi.org/10.1111/bjh.14101.
  • 16. Sancho JM, Navarro B, Soler Campos JA et al. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non- Hodgkin B-cell lymphomas. Eur J Haematol. 2020; 104(5): 499‐508. http://doi.org/10.1111/ejh.13392.
  • 17. Boyle EM, Morschhauser F. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf. 2015; 14(4): 601‐7. http://doi.org/10.1517/14740338.2015.1010505.
  • 18. Péan E, Flores B, Hudson I et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2013; 18(5): 625‐33. http://doi.org/10.1634/theoncologist.2013-0020.
  • 19. Barrenetxea Lekue C, Grasso Cicala S, Leppä S et al. Pixantrone beyond monotherapy: a review. Ann Hematol. 2019; 98(9): 2025‐33. http://doi. org/10.1007/s00277-019-03749-0.
  • 20. Engert A, Herbrecht R, Santoro A et al. EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma. 2006; 7(2): 152‐4. http://doi.org/10.3816/ CLM.2006.n.055.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-e70c2154-63b3-4061-bf72-e9225cd498d0
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.